Gnomica Biotherapy

Company Overview

Snapshot

Founded in June 2025 by Uri Kolodny and Ravid Straussman, Gnomica Biotherapy operates with 1–10 employees. The company has completed one funding round, securing seed capital in January 2026 to advance its novel cancer treatments.

Business overview

Gnomica Biotherapy is a Health Tech & Life Sciences company focused on developing innovative cancer treatments. The company's core technology involves small-molecule drug inhibitors designed to target bacterial functions within the human body, addressing a critical and often overlooked factor in cancer treatment resistance. Gnomica Biotherapy operates within the Pharma & Medical Biotechnology sector, specifically in Drugs Discovery & Development, and serves the Healthcare & Life Sciences market.

Company Intelligence Q&A

When was Gnomica Biotherapy founded?

Gnomica Biotherapy was founded in June 2025.

Who are the founders of Gnomica Biotherapy?

Uri Kolodny serves as Co-Founder & CEO, and Ravid Straussman is Co-Founder & Chief Scientist at Gnomica Biotherapy.

What is Gnomica Biotherapy's primary focus?

Gnomica Biotherapy is focused on pioneering novel cancer treatments by developing small-molecule drug inhibitors that target bacterial functions in the human body.

What is Gnomica Biotherapy's product development stage?

Gnomica Biotherapy's product offerings are currently in the Clinical Trial stage, indicating active development and testing of its small-molecule drug inhibitors.